News
The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
The United States Food and Drug Administration (FDA) has approved a twice-a-year injectable drug to be used for HIV ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.
FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...
Dailymotion on MSN4h
US FDA approves Gilead’s twice-yearly injection for HIV preventionThe US Food and Drug Administration approves Wednesday, June 18, Gilead Sciences lenacapavir, a twice-yearly injection, for ...
And more pharma news updates from Pharmalittle.
A twice-yearly injection of lenacapavir would offer near-complete protection against the virus, clinical date indicate. More pharmaceutical news is about Dupixent, GLP-1 results, and more.
In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.
In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results